Inocras, AimedBio team up for cancer treatments

Inocras has entered a strategic partnership with AimedBio to enhance cancer drug development using whole genome intelligence. Combining whole genome data with AimedBio’s drug development approach is expected to speed up clinical development. The collaboration enables AimedBio to use Inocras’ WGS technology and data analysis in trials. Credit: PeopleImages/Shutterstock.com. US-based precision medicine company Inocras has entered a strategic partnership with South Korean biopharmaceutical company AimedBio to enhance cancer drug development using whole genome intelligence. The deal includes a strategic equity investment by AimedBio in Inocras and a joint research agreement between the two companies. LOA and PTSR Model Incvax…

Source: Pharmaceutical Technology